Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine

Drug Safety

Volumn 21, Issue SUPPL. 1, 1999, Pages 45-61

  Segarra, Victor ^a   López, Manuel ^a   Ryder, Hamish ^a   Palacios, José Maria ^a   Roberts, David J ^a  

^a Almirall Prodesfarma ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; CETIRIZINE; CHLORPHENIRAMINE; CISAPRIDE; EBASTINE; HALOPERIDOL; TERFENADINE;

COMPUTER ANALYSIS; CONFERENCE PAPER; DRUG CONFORMATION; DRUG STRUCTURE; ELECTROCHEMISTRY; HYDROGEN BOND; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0343550533     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921001-00007     Document Type: Conference Paper

References (44)

1. Moragues J, Roberts DJ. Ebastine. Drugs Future 1990; 15: 674-9
2. Wiseman LR, Faulds D. Ebastine. A review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996; 51: 260-77
3. 1-receptor antagonist binding site. Pt 1. Active conformation of cyproheptatline. J Comput Aided Mol Des 1991; 5: 357-70
4. 1-receptor antagonists. Quant Struct Act Relatsh 1992; 11: 348-63
5. 1-receptor antagonists. Arzneimittel Forschung 1986; 36: 895-9
6. Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 34-56
7. Martínez-Tobed A, Tarrus E, Segura J, et al. Pharmacokinetic studies of ehastine in rats, dogs and man. Drugs Today 1992; 28 Suppl. B: 57-67
8. 1-receptor antagonist. Drugs Today 1992;28 Suppl. B: 11-21
9. 1 receptor antagonist. Drugs 1996; 52 Suppl. 1: 8-14
10. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
11. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-6
12. Crumb WJ, Wible B, Arnold DJ, et al. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 1995; 47: 181
13. 1 receptor antagonists on action potentials in guinea-pig isolated papillary muscles. Arch Int Pharmacodyn Ther 1996; 331: 59-73
14. Yang T, Prakash C, Roden DM, et al. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995; 115: 267-74
15. 1-reccptor antagonist on human Kv1.5 channels. Br J Pharmacol 1996; 118: 105P
16. Gras J, Llenas J, Palacios JM. Ebastine is without effect in a sensitive experimental model for detecting prolongation of the QTc interval. Allergy 1996; 51 Suppl. 31: 188
17. Hey JA, del Prado M, Sheerwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittel Forschung 1996; 46(1): 153-8
18. Roberts DJ, Llenas J. Second generation antihistamines and cardiotoxicity. Arzneimittel Forschung 1996; 46 (2): 832-4
19. Hey JA, del Prado M, Kreutner W, et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittel Forschung 1996; 46 (1): 159
20. 1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119: 187-8
21. Williams A, Redfern WS, Day A, et al. Prolongation of the QTc interval by ketoconazole in conscious guinea-pigs implanted with ECG telemetry transducers. Br J Pharmacol 1996; 119: 356P
22. ChemX version, Jan 1996. Oxfordshire, England: Chemical Design Limited, 1996
23. Davies EK, Murrall NW. How accurate does a force field need to be? Computers Chem 1989; 13: 149-56
24. 2 with manolide. J Med Chem 1993; 36: 1866-79
25. Gordon HL, Somarjai RL. Fuzzy cluster analysis of molecular dynamics trajectories. Proteins Struct Funct Genet 1992; 14: 249-64
26. Shenkin PS, McDonald DQ. Cluster analysis of molecular conformations. J Comput Chem 1994; 15: 899
27. SAS Release 6,10, Cary, North Carolina: SAS Institute Inc, 1993
28. MOPAC/AM1 method of version 6.00 (Bloomington, IN, USA: Quantum Chemistry Program Exchange (QCPE), Program no. 506), 1990. Program VSS (QCPE, Program no. 249), 1974
29. Stewart J, James P. MOPAC: a semiempirical molecular orbital program. J Comput Aided Mol Des 1990; 4: 1-105
30. Giessner-Prettre C, Pullman A. Molecular electrostatic potentials. Comparison ah initio and CNDO (Complete neglected of differential overlap) results. Theor Chim Acta (Berlin) 1972; 25: 83-8
31. GRID version 14. Oxford, England: Molecular Discovery Limited, 1994
32. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-57
33. Wade RC, Clark KJ, Goodford PJ. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. I. Ligand probe groups with the ability to form two hydrogen bonds. J Med Chem 1993; 36: 140-7
34. Wade RC, Goodford PJ. Further development of hydrogen bond functions for use in determining energetically favorable binding sites on molecules of known structure. 2. Ligand probe groups with the ability to form more than two hydrogen bonds. J Med Chem 1993; 36: 148-56
35. Boobbyer DNA, Goodford PJ, McWhinnie PM, et al. New hydrogen bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem 1989; 32: 1083-94
36. 1-antihistaminic agents in relation to their central sedative side-effects. Fur J Pharm Sci 1994; 2: 373-84
37. Albert A, Serjeant EP. The determination of ionization constants. London: Chapman and Hall Ltd, 1971
38. 1-antagonists and including a known interaction site on the receptor. J Med Chem 1995; 38: 3351-60
39. Rabinowitz JR, Namhoodiri K, Weinstein H. A finite expansion method for the calculation and interpretation of molecular electrostatic potentials. Int J Quantum Chem 1986; 29: 1697-704
40. Alkorta I, Villar HO. Molecular electrostatic potential of D1 and D2 dopamine agonists. J Med Chem 1994; 37: 210-3
41. Carrupt PA, El Tajar N, Karlén A, et al. Molecular electrostatic potentials for characterizing drug-biosystem interactions. Methods Enzymol 1991; 203: 638-77
42. Loew GH, Villar HO, Alkorta I. Strategies for indirect computer-aided drug design. Pharm Res 1993; 10: 475-86
43. Szymoniak J, Boudon A, Chrétien JR, et al. Drug design: LUMO control of neuroleptic pharmacophores [in French]. Eur J Med Chem 1987; 22: 101-7
44. Schweiger K, Weis R, Berthold H, et al. Computer assisted lead finding and optimization [abstract P-17.D]. Abstracts of the 11th European Symposium on Quantitative Structure Activity Relationships; 1996 Sep 1-6: Lausanne